Gantt Chart for Biotech Startup

Drug development is the longest, most capital-intensive product development process in any industry. A small molecule or biologic asset moves from hit identification to an approved drug in 10 to 15 years, traversing multiple phases of research, development, and clinical evaluation—each with defined endpoints that must be met before the next phase can begin. This linearity makes the biotech startup timeline ideal territory for a Gantt chart.

Unlike software projects where iteration can compress timelines, biotech development has hard sequential dependencies imposed by biology, regulatory science, and good manufacturing practice (GMP) manufacturing requirements. You cannot start a GLP toxicology study until you have a lead candidate. You cannot file an IND until GLP tox is complete. You cannot start Phase 1 until the IND is active. A Gantt chart makes these dependencies explicit and helps founders, investors, and scientific advisory board members understand where the program stands—and how long it will take to reach the next value-inflection milestone.

This guide walks through the major phases of a biotech startup Gantt chart from company formation through Phase 1 clinical trial completion and Series A fundraise.

Phase 1: Company Formation (Months 1–4)

Getting the company's legal and IP foundation right at the outset prevents costly problems later—at Series A due diligence, at partnership discussions, or at IPO.

Entity formation for a US biotech startup should almost always be a Delaware C-corporation. Delaware provides the most mature corporate law framework and is expected by institutional investors. Filing takes days; cap table setup and initial equity allocation to founders takes weeks. Engage a law firm that specializes in life sciences startups—generic startup law firms may not understand the nuances of IP assignment from academic institutions or the structure of milestone-based licensing arrangements.

IP assignment from founders must be completed immediately. All founders must assign any intellectual property related to the company's technology to the company before any work begins. Founders who delay IP assignment create due diligence problems that can kill financing rounds.

University technology license applies if the founding technology was developed at an academic institution. Negotiating a license from a university technology transfer office (TTO) requires time—typically 3 to 9 months—and involves complex terms: royalty rates on net sales (typically 1% to 5% for small molecule drugs), sublicensing fee provisions, milestone payments tied to development events (IND filing, Phase 1 completion, NDA approval), patent cost reimbursement obligations, and diligence requirements (timelines by which the company must hit development milestones to maintain the license). Engage IP counsel with specific TTO negotiation experience.

Seed funding for early-stage biotech comes from several sources: NIH SBIR/STTR grants (non-dilutive, up to $2M for Phase II SBIR), angel investors with life sciences backgrounds, pre-seed venture capital, and—for academic spinouts—the university's own venture fund or licensing equity. Build the fundraising workstream on the Gantt chart alongside legal formation; you will need capital to hire the first scientific employees.

Scientific advisory board (SAB) recruitment should begin immediately. SAB members with clinical expertise, key opinion leader status in the disease area, and investor networks are enormously valuable for early credibility. Most SAB members receive equity (0.1% to 0.5%) vesting over 2 to 4 years and a modest annual cash retainer.

Gantt allocation: 3 to 4 months for legal formation, IP assignment, and seed funding. TTO negotiation may run in parallel and extend 3 to 9 months beyond initial formation.

Phase 2: Research and Target Validation (Months 4–18)

Target validation establishes that your biological hypothesis is correct—that modulating the target you have selected produces the desired biological effect in disease-relevant models. Investors and partners treat this as the first major proof-of-concept milestone.

Target identification and validation begins in vitro. If you are developing a small molecule, you need biochemical assays demonstrating target engagement and cellular assays demonstrating functional activity in disease-relevant cell lines. If you are developing a biologic (monoclonal antibody, bispecific, ADC, cell therapy), you need binding and functional assays that confirm your molecule engages the target with the required affinity and selectivity.

Hit identification applies primarily to small molecule programs. High-throughput screening (HTS) against compound libraries of hundreds of thousands to millions of compounds is the traditional approach; structure-based drug design and DNA-encoded library (DEL) screening have become important alternatives. For biologics, antibody screening using hybridoma technology or phage display produces initial antibody candidates for further evaluation.

Lead candidate selection narrows the field from dozens or hundreds of hits to 1 to 5 lead candidates for optimization. Selection criteria include potency (how effective is it at the target?), selectivity (does it hit off-targets that could cause toxicity?), and early ADMET properties (does it have properties consistent with druggability?).

IP strategy runs in parallel with lead selection. File provisional patent applications within 12 months of any first public disclosure (conference presentation, paper submission) to preserve patent rights. Provisionals are inexpensive and buy 12 months before the full utility application must be filed.

Gantt allocation: 12 to 18 months from initial research to lead candidate selection. This phase is the most scientifically uncertain on the timeline.

Phase 3: Lead Optimization (Months 18–30)

Lead optimization is an iterative cycle of molecular design, synthesis or engineering, and testing. The goal is to produce one or a small number of development candidates that meet predefined nomination criteria.

Medicinal chemistry (for small molecules) or antibody engineering (for biologics) iterates on the lead structure to improve potency, selectivity, and drug-like properties. Each iteration generates 20 to 50 new analogs or variants for testing, with structure-activity relationship (SAR) analysis guiding the next design cycle. This is typically 3 to 6 design-make-test cycles over 12 to 18 months.

ADMET profiling measures the absorption, distribution, metabolism, excretion, and toxicity properties of lead compounds. Key assays include: aqueous solubility (affects formulation), metabolic stability in liver microsomes (affects dosing frequency), plasma protein binding (affects free drug concentration), permeability (affects bioavailability for oral drugs), CYP inhibition (affects drug-drug interaction liability), hERG binding (affects cardiac safety liability), and genotoxicity (Ames test, micronucleus assay).

Candidate nomination selects the 1 to 3 compounds that meet all predefined nomination criteria across efficacy, selectivity, and ADMET to advance into preclinical development. Candidate nomination is a major value inflection point and is often the milestone that triggers a seed extension or Series A financing conversation.

Gantt allocation: 12 to 18 months of lead optimization, with candidate nomination at the end of this phase.

Phase 4: Preclinical Development (Months 30–48)

Preclinical development generates the data package required to support an Investigational New Drug (IND) application to the FDA (or equivalent application to EMA, PMDA, or other regulatory authority). This is the most capital-intensive pre-IND phase.

In vitro efficacy models establish that the drug candidate produces the desired effect in human cell-based disease models. Organoids, co-cultures, and patient-derived primary cells are increasingly used alongside traditional cell lines.

In vivo pharmacology demonstrates efficacy in animal models of the disease. The gold standard is a validated rodent disease model, with pharmacokinetic/pharmacodynamic (PK/PD) modeling to establish the relationship between drug exposure and effect. The in vivo efficacy package must demonstrate that the drug produces meaningful disease modification at exposures that are achievable and tolerable in animals.

GLP toxicology studies are the regulatory cornerstone of the IND package. Good Laboratory Practice (GLP) toxicology studies are conducted at accredited CROs under strict quality systems. The typical package for a small molecule includes a 28-day repeat-dose toxicology study in two species (rodent and non-rodent, typically rat and dog or rat and monkey), with a 28-day recovery group, full clinical pathology and histopathology, and a toxicokinetic substudy. A 90-day study is required to support a Phase 1 trial longer than 28 days. Genotoxicity studies (Ames test, in vitro micronucleus, and in vivo micronucleus) are required. These studies take 6 to 12 months and cost $1.5M to $5M for a standard package.

Chemistry, Manufacturing, and Controls (CMC) covers the manufacturing of the drug substance and drug product for clinical use. This includes process development (how is the molecule synthesized or produced at scale?), analytical method development (how is purity, potency, and stability measured?), formulation development (what is the clinical dosage form—tablet, capsule, IV solution?), and GMP manufacturing of clinical trial material (CTM). GMP manufacturing for Phase 1 requires a registered CMO and takes 6 to 12 months after process transfer. Budget $2M to $8M for CMC through Phase 1.

Gantt allocation: 18 to 24 months, with GLP tox and CMC as the rate-limiting paths. GLP tox and CMC often run in parallel to compress the overall timeline.

Phase 5: IND Filing (Months 46–52)

The IND application is the regulatory submission that allows a company to begin clinical trials in the United States. The FDA has 30 days after IND receipt to place a clinical hold or allow the study to proceed. In practice, most well-prepared INDs receive implicit clearance—the 30 days pass without an FDA response, and the clinical trial can begin.

Pre-IND meeting with the FDA is optional but strongly recommended for novel mechanisms, complex patient populations, or any regulatory uncertainty. The FDA will provide written responses to your questions (typically within 30 days of the meeting request being granted), which are invaluable for shaping the clinical protocol and GLP tox package to avoid a clinical hold.

IND application writing organizes the preclinical data package into the FDA-required structure: the Investigator's Brochure (comprehensive summary of non-clinical and any clinical data), the pharmacology/toxicology section (GLP tox study reports), the CMC section (description of the drug substance and drug product, manufacturing processes, and stability data), and the clinical protocol with supporting documents (informed consent form template, investigator qualifications, IRB approval process).

Gantt allocation: 4 to 6 months for IND writing and FDA review period.

Phase 6: Phase 1 Clinical Trial (Months 52–72)

Phase 1 establishes the safety, tolerability, and pharmacokinetics of the drug in humans. For oncology programs, Phase 1 often includes an expansion cohort designed to generate early efficacy signals. For non-oncology programs, Phase 1 is typically conducted in healthy volunteers.

Site selection, initiation (site contracts, IRB approval, clinical investigator training), and patient recruitment are the operational workstreams. A first-in-human trial typically begins with sentinel dosing (1 to 3 patients at the lowest dose level are treated and observed for 1 to 4 weeks before additional patients are enrolled), then dose escalation guided by a Data Safety Monitoring Board (DSMB) reviewing safety data at each dose level.

Top-line Phase 1 results and the Phase 1 clinical study report are the major outputs of this phase, and are the primary dataset for a Series A or Series B fundraise.

Building the Biotech Gantt Chart

A biotech startup Gantt chart spanning 5 to 6 years requires a tool that handles long timelines without becoming unwieldy. A free online Gantt chart maker lets founding teams and boards see the full development arc—from company formation to Phase 1 completion—on a single timeline, with quarterly or annual resolution for the later phases and weekly resolution for the near-term activities.

Use the Gantt chart in board meetings and investor presentations to show where the program stands against plan. When GLP tox takes longer than expected (it frequently does) or CMC hits a manufacturing issue, the Gantt chart makes the downstream impact on the IND timeline immediately visible—enabling early communication with investors rather than a surprise delay.

Biotech is a timeline-driven business. Plan the timeline with precision, manage it actively, and communicate it clearly.